Skip to content
alexsl
- Citizens upgraded Allogene Therapeutics (ALLO) to market Outperform citing its discounted EPS and a revenue multiple analysis.
- The bank has a $5 price target (~236% upside based on Jan. 8 close).
- Analyst Reni Benjamin said that prior data on lead
